Effect of body mass index and cholesterol‐rich apolipoprotein‐B‐containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors‐based therapy: A retrospective analysis

Documenti analoghi

• Immune‐related adverse events in immune checkpoint inhibitor therapy for cancer
  di: Katie Liao, et al.
  Pubblicazione: (2025)
• Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
  di: Saira Afzal, et al.
  Pubblicazione: (2024)
• Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
  di: Guiming Deng, et al.
  Pubblicazione: (2024)
• Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
  di: Pengcheng Zhu, et al.
  Pubblicazione: (2024)
• A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
  di: Yuki Haruta, et al.
  Pubblicazione: (2024)